GSK to start phase 3 trials of low-carbon Ventolin inhaler in 2024
London: GSK plc has announced it will start Phase III trials of a low carbon version of its metered dose inhaler (MDI), Ventolin (salbutamol), using a next generation propellant, in 2024. If successful, it has the potential to reduce greenhouse gas emissions from use of the inhaler by approximately 90%, significantly contributing to GSK’s ambitious net-zero climate targets.
Thirty-five million patients with respiratory conditions around the world rely on this inhaler as their rescue medication. However, it accounts for close to half (49%) of GSK’s carbon footprint, as well as contributing to the carbon footprint of global health systems. Significantly reducing the carbon footprint of the propellant in the inhaler is a key milestone in the company’s pathway to net zero.
GSK is investing in a R&D programme to redevelop the inhaler by transitioning to a lower carbon propellant. The next-generation propellant, which has been under technical development for several years, has been tested extensively to ensure suitability for MDIs and patient use. Recent data from early clinical trials has supported the decision to progress to phase III and dosing of first patients is planned in the first half of 2024. If successful, regulatory submissions will begin in 2025.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.